It is notoriously hard to treat effectively. Saphnelo will compete in the market most closely with GlaxoSmithKline's BLyS inhibitor Benlysta (belimumab), which has been available in the EU to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback